United Therapeutics Launches $1 Billion Share Buyback

The latest update is out from United Therapeutics ( (UTHR) ).

On August 1, 2025, United Therapeutics Corporation announced the initiation of a $1 billion accelerated share repurchase program, reflecting confidence in its stock value and future growth prospects. The company entered into agreements with Citibank to repurchase shares, with settlements expected in late 2025 and early 2026, highlighting a strategic move to balance investment in growth with returning capital to shareholders.

The most recent analyst rating on (UTHR) stock is a Hold with a $319.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.

Spark’s Take on UTHR Stock

According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.

United Therapeutics’ strong financial performance and positive earnings call highlights are somewhat offset by bearish technical indicators. The company’s valuation is attractive, but market competition poses a risk moving forward.

To see Spark’s full report on UTHR stock, click here.

More about United Therapeutics

United Therapeutics Corporation is a public benefit corporation operating in the biotechnology and pharmaceutical industry. The company focuses on developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs, aiming to address unmet medical needs and benefit stakeholders.

Average Trading Volume: 547,068

Technical Sentiment Signal: Hold

Current Market Cap: $12.42B

For an in-depth examination of UTHR stock, go to TipRanks’ Overview page.